Related Experiment Video
Updated: Mar 13, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
84.7K
How I use anticoagulation in atrial fibrillation
1Division of Cardiovascular Medicine, University of Utah Health Sciences Center, Salt Lake City, UT.
Blood
|October 27, 2016
Summary
Oral anticoagulation (OAC) prevents stroke in atrial fibrillation. Non-vitamin K antagonist oral anticoagulants (NOACs) are preferred over warfarin for eligible patients, but selection among NOACs requires careful consideration.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Atrial fibrillation (AF) is a common arrhythmia linked to increased stroke and embolism risk.
- Oral anticoagulation (OAC) is crucial for preventing thromboembolism in AF patients.
- CHA2DS2-VASc score guides stroke risk assessment in non-valvular AF.
Observation:
- Patients with elevated CHA2DS2-VASc scores require evaluation for non-vitamin K antagonist oral anticoagulant (NOAC) therapy.
- Eligibility for NOACs depends on assessing valve disease and renal function.
- NOACs demonstrate superior safety and efficacy compared to warfarin as a group.
Findings:
- No direct randomized trials compare individual NOACs, complicating selection.
- Certain patient populations are underrepresented in clinical trials, necessitating clinical judgment.
- Emerging trial data will aid physician decision-making.
Implications:
- Patient engagement is vital for optimizing OAC management and health outcomes.
- Further research is needed to guide NOAC selection in diverse patient groups.
- Personalized OAC strategies are essential for balancing risks and benefits in AF management.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.6K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.6K
01:29Venous Thrombosis III: Interprofessional Care
445
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
445
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
01:16Clot Retraction and Fibrinolysis
9.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.9K
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
606
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
606